Guangzhou Wondfo BiotechLtd's (SZSE:300482) Earnings Have Declined Over Three Years, Contributing to Shareholders 56% Loss
Guangzhou Wondfo BiotechLtd's (SZSE:300482) Earnings Have Declined Over Three Years, Contributing to Shareholders 56% Loss
Guangzhou Wondfo Biotech Co.,Ltd (SZSE:300482) shareholders should be happy to see the share price up 18% in the last month. But that doesn't change the fact that the returns over the last three years have been disappointing. Regrettably, the share price slid 57% in that period. Some might say the recent bounce is to be expected after such a bad drop. After all, could be that the fall was overdone.
廣州萬富生物技術有限公司, Ltd(深圳證券交易所代碼:300482)的股東應該很高興看到上個月股價上漲了18%。但這並不能改變過去三年的回報令人失望的事實。遺憾的是,在此期間,股價下跌了57%。有人可能會說,在經歷瞭如此嚴重的跌幅之後,最近的反彈是可以預料的。畢竟,可能是秋天過頭了。
On a more encouraging note the company has added CN¥447m to its market cap in just the last 7 days, so let's see if we can determine what's driven the three-year loss for shareholders.
更令人鼓舞的是,該公司的市值在過去7天內就增加了4.47億元人民幣,因此,讓我們看看我們能否確定股東三年虧損的原因。
There is no denying that markets are sometimes efficient, but prices do not always reflect underlying business performance. By comparing earnings per share (EPS) and share price changes over time, we can get a feel for how investor attitudes to a company have morphed over time.
不可否認,市場有時是有效的,但價格並不總是能反映潛在的業務表現。通過比較每股收益(EPS)和一段時間內的股價變化,我們可以了解投資者對公司的態度是如何隨着時間的推移而變化的。
Guangzhou Wondfo BiotechLtd saw its EPS decline at a compound rate of 19% per year, over the last three years. This reduction in EPS is slower than the 25% annual reduction in the share price. So it's likely that the EPS decline has disappointed the market, leaving investors hesitant to buy.
在過去三年中,廣州萬富生物科技有限公司的每股收益複合下降幅度爲每年19%。每股收益的下降低於股價每年25%的降幅。因此,每股收益的下降很可能令市場失望,使投資者對買入猶豫不決。
The company's earnings per share (over time) is depicted in the image below (click to see the exact numbers).
該公司的每股收益(隨着時間的推移)如下圖所示(點擊查看確切數字)。
![earnings-per-share-growth](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240304/0-6788e082a299cfc6c230c85b77b4b419-0-724ff06bf28361207b2dafa80181ca50.png/big)
This free interactive report on Guangzhou Wondfo BiotechLtd's earnings, revenue and cash flow is a great place to start, if you want to investigate the stock further.
如果你想進一步調查該股,這份關於廣州Wondfo BiotechLtd的收益、收入和現金流的免費互動報告是一個很好的起點。
A Different Perspective
不同的視角
Guangzhou Wondfo BiotechLtd shareholders are down 16% over twelve months (even including dividends), which isn't far from the market return of -16%. The silver lining is that longer term investors would have made a total return of 3% per year over half a decade. If the fundamental data remains strong, and the share price is simply down on sentiment, then this could be an opportunity worth investigating. It's always interesting to track share price performance over the longer term. But to understand Guangzhou Wondfo BiotechLtd better, we need to consider many other factors. Consider for instance, the ever-present spectre of investment risk. We've identified 3 warning signs with Guangzhou Wondfo BiotechLtd , and understanding them should be part of your investment process.
廣州萬富生物科技有限公司的股東在十二個月內下跌了16%(甚至包括股息),與-16%的市場回報率相差不遠。一線希望是,長期投資者將在五年內獲得每年3%的總回報。如果基本面數據仍然強勁,而股價僅因市場情緒而下跌,那麼這可能是一個值得研究的機會。長期跟蹤股價表現總是很有意思的。但是,要更好地了解廣州萬富生物技術有限公司,我們需要考慮許多其他因素。例如,投資風險的幽靈無處不在。我們已經向廣州萬富生物技術有限公司確定了三個警告信號,了解它們應該是您投資過程的一部分。
If you are like me, then you will not want to miss this free list of growing companies that insiders are buying.
如果你像我一樣,那麼你不會想錯過這份業內人士正在收購的成長型公司的免費名單。
Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Chinese exchanges.
請注意,本文引用的市場回報反映了目前在中國交易所交易的股票的市場加權平均回報。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對這篇文章有反饋嗎?對內容感到擔憂?直接聯繫我們。 或者,給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。